Leidos Wins $317.9 Million US Defense Health Agency Contract
Leidos has secured a $317.9 million contract with the US Defense Health Agency. The company's stock is currently trading at $119.70, with a 5-day change of -1.56%. Goldman Sachs recently adjusted its price target for Leidos to $127 from $132.
How this was made
The 30-second read
Why it matters
The award adds a sizable, multi‑year revenue stream, likely improving earnings guidance and investor sentiment.
Market read
A new $317.9 M defense contract is a material catalyst for Leidos and may lift the broader defense sector.
What to watch
Potential cost overruns or future budget cuts could temper upside.
Background
Leidos (LDX) is a major U.S. defense and IT services firm; the Defense Health Agency contract supports medical IT systems for the military.
Market effects
Boosts outlook for the defense and government‑contracting sector.
U.S. defense contractors may see modest gains.
Limited to defense‑related equities; no broad market effect.
Counterpoint
If the contract faces execution risk, the stock could be over‑priced on hype.
Key entities
- CompanyLeidos Holdings, Inc.
U.S. defense contractor and IT services provider.
- Government AgencyU.S. Defense Health Agency
Federal agency overseeing health services for the armed forces.



